Compare HIPO & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIPO | AURA |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | 540 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 748.8M | 713.4M |
| IPO Year | N/A | 2021 |
| Metric | HIPO | AURA |
|---|---|---|
| Price | $27.76 | $7.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $38.67 | $20.00 |
| AVG Volume (30 Days) | 160.9K | ★ 602.2K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.28 | N/A |
| Revenue Next Year | $22.33 | N/A |
| P/E Ratio | $7.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.08 | $4.73 |
| 52 Week High | $38.98 | $9.54 |
| Indicator | HIPO | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 52.02 |
| Support Level | $27.00 | $6.58 |
| Resistance Level | $29.43 | $7.83 |
| Average True Range (ATR) | 0.97 | 0.35 |
| MACD | -0.21 | 0.02 |
| Stochastic Oscillator | 30.71 | 64.63 |
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.